ATE540115T1 - Nukleinsäurekonstruktsysteme mit fähigkeit zur diagnose oder behandlung eines zellzustands - Google Patents

Nukleinsäurekonstruktsysteme mit fähigkeit zur diagnose oder behandlung eines zellzustands

Info

Publication number
ATE540115T1
ATE540115T1 AT08776602T AT08776602T ATE540115T1 AT E540115 T1 ATE540115 T1 AT E540115T1 AT 08776602 T AT08776602 T AT 08776602T AT 08776602 T AT08776602 T AT 08776602T AT E540115 T1 ATE540115 T1 AT E540115T1
Authority
AT
Austria
Prior art keywords
nucleic acid
transcriptional regulatory
acid construct
mammalian transcriptional
diagnose
Prior art date
Application number
AT08776602T
Other languages
English (en)
Inventor
Lior Nissim
Roy Bar-Ziv
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE540115T1 publication Critical patent/ATE540115T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AT08776602T 2007-07-11 2008-07-10 Nukleinsäurekonstruktsysteme mit fähigkeit zur diagnose oder behandlung eines zellzustands ATE540115T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92973607P 2007-07-11 2007-07-11
US61930707P 2007-12-28 2007-12-28
PCT/IL2008/000963 WO2009007980A1 (en) 2007-07-11 2008-07-10 Nucleic acid construct systems capable of diagnosing or treating a cell state

Publications (1)

Publication Number Publication Date
ATE540115T1 true ATE540115T1 (de) 2012-01-15

Family

ID=46705097

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08776602T ATE540115T1 (de) 2007-07-11 2008-07-10 Nukleinsäurekonstruktsysteme mit fähigkeit zur diagnose oder behandlung eines zellzustands

Country Status (5)

Country Link
US (2) US20100197767A1 (de)
EP (2) EP2500428A3 (de)
AT (1) ATE540115T1 (de)
IL (1) IL203195A0 (de)
WO (1) WO2009007980A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150211041A1 (en) * 2012-08-16 2015-07-30 Yeda Research And Development Co., Ltd. Programmable nor-based device for transcription profile analyses
WO2018169901A1 (en) * 2017-03-13 2018-09-20 Massachusetts Institute Of Technology Synthetic promoters
CN120665951A (zh) * 2018-02-07 2025-09-19 吉尼松公司 杂合调控元件
WO2020072471A1 (en) * 2018-10-05 2020-04-09 University Of Utah Research Foundation Methods of making platelets comprising modified receptors and uses thereof
WO2020261277A1 (en) 2019-06-25 2020-12-30 Migal Galilee Research Institute Ltd. SYSTEMS AND USES THEREOF FOR CREATING SYNTHETIC TRANSCRIPTIONAL LOGIC 'AND' GATES BASED ON PRE-mRNA TRANS-SPLICING
CN116059405A (zh) * 2022-09-26 2023-05-05 华中科技大学同济医学院附属协和医院 一种治疗恶性肿瘤且具备特异性与灵敏度的合成基因网络系统
WO2024189614A1 (en) * 2023-03-12 2024-09-19 Circuit Bio Ltd. Tissue specific synthetic promoters and circuits and use thereof
CN121221507B (zh) * 2025-12-04 2026-02-06 康柏利科技（苏州）有限公司 一种抗炎舒缓的化妆品组合物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1995013375A1 (en) * 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
AU1662595A (en) * 1994-01-28 1995-08-15 Herbert Altmann Method of determining the activity of a regulatory factor, and use of the method
US6458559B1 (en) * 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
US6706491B1 (en) * 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
WO2000066707A2 (en) * 1999-05-03 2000-11-09 Technion Research And Development Foundation Ltd. Novel thiamine transporter, a polynucleotide encoding same and their uses
WO2007143451A2 (en) * 2006-05-30 2007-12-13 Terman David S Targeted delivery of oncolytic viruses, anti-tumor proteins, plasmids, toxins, hemolysins & chemotherapy
WO2001025420A2 (en) * 1999-10-07 2001-04-12 Hybrigen, Inc. Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
US6251676B1 (en) * 2000-03-24 2001-06-26 The General Hospital Corporation Mammalian cell two-hybrid system
WO2001083808A2 (en) * 2000-05-01 2001-11-08 Rappaport Family Institute For Research In The Medical Sciences Nucleic acid construct system and method utilizing same useful for identifying protein-protein interactions
WO2001096373A2 (en) * 2000-06-14 2001-12-20 Clontech Laboratories, Inc. Fluorescent timer proteins and methods for their use
US6787321B1 (en) * 2000-10-13 2004-09-07 The Regents Of The University Of California Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
US7060459B2 (en) * 2000-12-08 2006-06-13 Juan Saus TNF-inducible promoters and methods for using
JP2004536572A (ja) * 2001-02-23 2004-12-09 セル・ジェネシス・インコーポレイテッド 新規ベクター構築物
AU2002303282A1 (en) * 2001-04-06 2002-10-21 University Of Rochester Suppression of androgen receptor transactivation through new pathways to AR and AR coactivators and repressors
JP4528623B2 (ja) * 2002-09-16 2010-08-18 プロメガ コーポレイション 迅速分解性レポーター融合タンパク質
WO2004078984A1 (en) * 2003-03-05 2004-09-16 Janssen Pharmaceutica N.V. Animal model for the fast identification of pharmaceutical active compounds in vivo
GT200600210A (es) * 2005-05-19 2007-01-03 Schering Ag Terapia genica de interferon-beta usdando un sistema mejorado de expresion regulada
WO2007002563A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators

Also Published As

Publication number Publication date
EP2500428A2 (de) 2012-09-19
US20100197767A1 (en) 2010-08-05
EP2500428A3 (de) 2012-12-26
IL203195A0 (en) 2011-08-01
EP2176409B1 (de) 2012-01-04
EP2176409A1 (de) 2010-04-21
US20130260386A1 (en) 2013-10-03
WO2009007980A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
Mattila et al. Reactive oxygen species: reactions and detection from photosynthetic tissues
IL203195A0 (en) Nucleic acid construct systems capable of diagnosing or treating a cell state
AR079972A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
MX2013007678A (es) Moleculas de acido nucleico dirigidas ala pequeña proteina de union de gtp rho1 y que confieren resistencia a las plagas de coleopteros.
EA201892761A1 (ru) Новые химерные инсектицидные белки, токсичные или ингибиторные в отношении чешуекрылых-вредителей
MX2017010721A (es) Interruptores transcripcionales activados mediante unión y métodos para su uso.
AR079881A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
UA108646C2 (xx) Клостридіальні токсини, що руйнуються
MX2010004305A (es) Plantas que tienen rasgos relacionados con el rendimiento aumentado y un metodo para producirlas.
AR080353A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
EP2845903A3 (de) Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zur Herstellung davon
AR079883A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
MX2015004060A (es) 3-epimerasa.
UA115022C2 (uk) Трансгенна рослина, яка містить нуклеїнову кислоту, що має виділену нуклеотидну послідовність, яка кодує модифіковану інтеїном ксиланазу
AR089828A1 (es) Variantes de lipasa y polinucleotidos que las codifican
MX2009011287A (es) Defensina de planta modificada.
WO2014202622A3 (en) Rasamsonia gene and use thereof
MX2011004483A (es) Leucolectinas y sus usos.
UY35366A (es) ?genes de toxina y métodos para su uso?.
BR112014019237A8 (pt) Uso de soluções contendo ácido glutâmico - ácido n,n-diacético ou um sal deste (glda) e/ou metilglicina - ácido n,n-diacético ou um sal deste (mgda), no tratamento de formações subterrâneas; e sistema contendo um material que contém aço-carbono, em contato com uma solução contendo ácido glutâmico - ácido n,n-diacético ou um sal deste (glda) e/ou metilglicina - ácido n,n-diacético ou um sal deste (mgda)
AR106430A1 (es) Generación de plantas de maíz con resistencia mejorada al tizón norteño de las hojas
CL2013001621A1 (es) Molecula de acido nucleico reguladora con especificidad definida, construccion de expresion que la comprende, vector; microorganismo, celula vegetal o animal; y metodo para la produccion de dicha molecula.
ATE530574T1 (de) Für ein utrophintranskriptionsspezifisches regulatorprotein kodierende nukleinsäure, damit kodiertes protein und verwendung
MX2015001542A (es) Metodo.
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188